Overview

Oyvind Dahle is an associate and intellectual property lawyer with Foley & Lardner LLP. He is a member of the firm’s Chemical, Biotechnology & Pharmaceutical Practice.

Oyvind works with clients on technologies such as chemical compounds and polymers, pharmaceutical compositions and delivery systems, immunotherapeutics, stem cell therapy, diagnostic methods, DNA sequencing and other genotyping methods, and medical devices. In addition to drafting and prosecuting patents, Oyvind has experience with providing opinions on patentability, invalidity, freedom-to-operate and representing patent owner in inter partes reviews before the Patent Trial and Appeal Board.

Oyvind joined Foley & Lardner as a summer associate in 2016, and prior to that he externed at the United States Patent and Trademark Office, Office of Patent Legal Administration, where he gained experience in patent examination procedures and assessments. Before pursuing his legal career, Oyvind worked at Leidos, Inc. as a scientist, at National Cancer Institute in its Laboratory of Protein Dynamics and Signaling as a research fellow, and at National Cancer Institute in its Experimental Immunology Branch as a postdoctoral fellow.

Education

  • American University Washington College of Law (J.D., 2017)
  • University of Oslo, Norway (Ph.D., 2014; M.S. 2000)
    • Majored in biochemistry
  • University of Oslo, Norway (B.S., 1998)
    • Majored in chemistry

Admissions

  • District of Columbia
  • United States Patent and Trademark Office

Selected Publications and Presentations

  • Author, “The Absurdity of Patent Ineligible Categories: The Discrepancy Between the Ariosa and Cellzdirect Decisions Highlights the Problems Created by Formalistic Adjudication of Patent Eligibility,” Wake Forest Journal of Business and Intellectual Property Law, Vol. 17 No. 1 (2016)
  • Co-author, “Inhibiting Smad2/3 Signaling in Pluripotent Mouse Embryonic Stem Cells Enhances Endoderm Formation by Increasing Transcriptional Priming of Lineage-Specifying Target Genes,” Developmental Dynamics, Vol. 245 Issue 7 (2016)
  • Co-author, “Polycomb Determines Responses to Smad2/3 Signaling in Embryonic Stem Cell Differentiation and in Reprogramming,” Stem Cells, Vol. 31 Issue 8 (2013)
  • Presenter, “Epigenetics in Development Polycomb Determines Smad2/3 Responses During Cell Fate Transitions in Stem Cell Differentiation and Reprogramming,” National Institutes of Health, Maryland (2013)
  • Co-author, “Nodal Signaling Recruits Histone Demethylase Jmjd3 to Counteract Polycomb Repression at Target Genes,” Science Signaling, Vol. 3 Issue 127 (2010)
  • Co-author, “FLASH Acts as a Co-activator of the Transcription Factor c-Myb and Localizes to Active RNA Polymerase II Foci,” Oncogene, Vol. 27 (2008)
  • Co-author, “The Chromatin Remodeling Factor Mi-2 Acts as a Novel Co-activator for Human c-Myb,” The Journal of Biological Chemistry, Vol. 282 (2007)
  • Co-author, “Coreceptor Signal Strength Regulates Positive Selection but Does Not Determine CD4/CD8 Lineage Choice in a Physiologic in Vivo Model,” The Journal of Immunology, Vol. 177 Issue 10 (2006)
  • Co-author, “PML Mediates IFN-alpha-induced Apoptosis in Myeloma by Regulating TRAIL Induction,” Blood, Vol. 105 (2005)
  • Co-author, “c-Myb Associates with PML in Nuclear Bodies in Hematopoietic Cells,” Experimental Cell Research, Vol. 297 Issue 1 (2004)
  • Co-author, “Transactivation Properties of c-Myb Are Critically Dependent on Two SUMO-1 Acceptor Sites That Are Conjugated in a PIASy Enhanced Manner,” European Journal of Biochemistry, Vol. 270 (2003)
  • Co-author, “JAB1/CSN5 Interacts with the GAL4 DNA Binding Domain: A Note of Caution About Two-Hybrid Interactions,” Biochimie, Vol. 83 Issue 10 (2001)

Languages

  • Norwegian

Insights